Additive effects of cannabinoid CB1 receptors blockade and cholecystokinin on feeding inhibition

Pharmacol Biochem Behav. 2011 Apr;98(2):220-6. doi: 10.1016/j.pbb.2010.12.007. Epub 2010 Dec 14.

Abstract

Cannabinoid CB1 receptor and cholecystokinin-1 (CCK(1)) receptors are located in peripheral nerve terminals of the gut, where they mediate satiety signals. Here we describe a detailed analysis of the interaction of both receptors in the control of feeding of food-deprived rats. Male Wistar rats were deprived for food 24h before testing. Rats were pre-treated with SR141716A (Rimonabant) or WIN 55,212-2 before CCK-8 sulphated administration and tested for food intake 60, 120 and 240 min after last drug injection. In parallel, the effect of Lorglumide--a CCK(1) receptor antagonist--pre-treatment was evaluated on feeding behaviour after SR141716A administration. Results show that SR141716A activates c-Fos expression in brainstem areas receiving vagal inputs. Blockade of CB1 receptors with SR141716A (1 mg/kg) reduces feeding and display additive satiety induction with the CCK(1) receptor agonist CCK-8 sulphated (5, 10, 25 μg/kg). The effect of SR141716A is not blocked by Lorglumide (10 mg/kg), indicating independent sites of action. Conversely, the administration of the CB1 agonist WIN 55,212-2 (2 mg/kg) reduced satiety induced by CCK-8. In conclusion, these results report additive anorectic actions for CCK1 activation and peripheral CB1 receptor blockade providing a framework for combined therapies in the treatment of eating disorders.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anorexia / etiology
  • Anorexia / physiopathology
  • Benzoxazines / administration & dosage
  • Brain / drug effects
  • Brain / physiology
  • Drug Synergism
  • Feeding Behavior / drug effects*
  • Feeding Behavior / physiology*
  • Gene Expression / drug effects
  • Genes, fos / drug effects
  • Male
  • Morpholines / administration & dosage
  • Naphthalenes / administration & dosage
  • Piperidines / administration & dosage
  • Proglumide / administration & dosage
  • Proglumide / analogs & derivatives
  • Pyrazoles / administration & dosage
  • Rats
  • Rats, Wistar
  • Receptor, Cannabinoid, CB1 / agonists
  • Receptor, Cannabinoid, CB1 / antagonists & inhibitors*
  • Receptor, Cannabinoid, CB1 / physiology
  • Receptor, Cholecystokinin B / antagonists & inhibitors
  • Rimonabant
  • Sincalide / administration & dosage*

Substances

  • Benzoxazines
  • Morpholines
  • Naphthalenes
  • Piperidines
  • Pyrazoles
  • Receptor, Cannabinoid, CB1
  • Receptor, Cholecystokinin B
  • (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
  • Proglumide
  • lorglumide
  • Sincalide
  • Rimonabant